Celyad SA (CYAD) - Total Assets
Based on the latest financial reports, Celyad SA (CYAD) holds total assets worth €5.70 Million EUR (≈ $6.66 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Celyad SA (CYAD) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Celyad SA - Total Assets Trend (2010–2024)
This chart illustrates how Celyad SA's total assets have evolved over time, based on quarterly financial data. See Celyad SA net assets for net asset value and shareholders' equity analysis.
Celyad SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Celyad SA's total assets of €5.70 Million consist of 65.6% current assets and 34.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 42.3% |
| Accounts Receivable | €908.00K | 9.2% |
| Inventory | €417.00K | 4.2% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €405.00K | 4.1% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Celyad SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CYAD company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celyad SA's current assets represent 65.6% of total assets in 2024, an increase from 37.0% in 2010.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2024, up from 21.9% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 58.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 9.2% of total assets.
Celyad SA Competitors by Total Assets
Key competitors of Celyad SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Celyad SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 3.59 | 2.73 |
| Quick Ratio | 0.59 | 3.04 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €-1.26 Million | €6.25 Million | €18.64 Million |
Celyad SA - Advanced Valuation Insights
This section examines the relationship between Celyad SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.40 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | -39.0% |
| Total Assets | €9.93 Million |
| Market Capitalization | $8.95 Million USD |
Valuation Analysis
Near Book Valuation: The market values Celyad SA's assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Celyad SA's assets decreased by 39.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celyad SA (2010–2024)
The table below shows the annual total assets of Celyad SA from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €9.93 Million ≈ $11.61 Million |
-39.02% |
| 2023-12-31 | €16.28 Million ≈ $19.04 Million |
-17.42% |
| 2022-12-31 | €19.72 Million ≈ $23.05 Million |
-75.34% |
| 2021-12-31 | €79.94 Million ≈ $93.46 Million |
+20.97% |
| 2020-12-31 | €66.08 Million ≈ $77.26 Million |
-26.44% |
| 2019-12-31 | €89.84 Million ≈ $105.03 Million |
-4.73% |
| 2018-12-31 | €94.30 Million ≈ $110.25 Million |
+21.48% |
| 2017-12-31 | €77.63 Million ≈ $90.75 Million |
-44.08% |
| 2016-12-31 | €138.81 Million ≈ $162.28 Million |
-12.99% |
| 2015-12-31 | €159.53 Million ≈ $186.50 Million |
+262.75% |
| 2014-12-31 | €43.98 Million ≈ $51.41 Million |
+35.79% |
| 2013-12-31 | €32.39 Million ≈ $37.86 Million |
+135.60% |
| 2012-12-31 | €13.75 Million ≈ $16.07 Million |
+99.87% |
| 2011-12-31 | €6.88 Million ≈ $8.04 Million |
-60.69% |
| 2010-12-31 | €17.50 Million ≈ $20.45 Million |
-- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more